Streetbeat News

Stock Prices

SE

Sea shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $84 to $78.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:26 am

BTCUSD

COIN

The German Government transferred 400 BTC, valued at approximately $24.34 million, to major cryptocurrency exchanges Coinbase Inc. (NASDAQ:COIN) and Kraken. This follows a previous transfer of 1,700 BTC to Coinbase, Bitstamp, and Kraken. The crypto community is closely monitoring these actions, which may influence short-term market dynamics.

Portfolio Pulse from Murtuza Merchant

June 25, 2024 | 11:25 am

POOL

Pool shares are trading lower after the company cut its FY24 EPS guidance due to declining year-to-date sales and lower-than-expected Q2 2024 revenues.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:24 am

GE

GE Aerospace shares are trading lower after its customer, Airbus, cut its 2024 targets.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:20 am

DOGEUSD

SHIBUSD

Pseudonymous trader Dark Crypto Lord discusses the challenging conditions in the current cryptocurrency market, highlighting the shift from long-term investments to speculative meme coins. He criticizes the tokenomics of new projects and the impact of venture capitalists dumping tokens. The FTX collapse has left a lasting negative impact, and the market now requires significant positive events to restore confidence.

Portfolio Pulse from Khyathi Dalal

June 25, 2024 | 11:18 am

GRAL

ILMN

Illumina Inc. (NASDAQ:ILMN) announced the spin-off of Grail Inc. (NASDAQ:GRAL), a cancer blood test developer, which will start trading independently on NASDAQ. Illumina shareholders will receive one share of GRAL for every six shares of ILMN. Illumina will retain a 14.5% stake in Grail. The spin-off follows regulatory challenges and a significant fine from the European Commission. Grail's CEO highlighted the potential of their cancer blood test, Galleri, which is undergoing clinical trials to support FDA approval by 2026.

Portfolio Pulse from Vandana Singh

June 25, 2024 | 11:17 am

AUR

UBER

Aurora and Uber Freight are collaborating to democratize driverless trucks for carriers of all sizes. This initiative is part of their ongoing partnership to integrate and deploy autonomous trucks on the Uber Freight network.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:13 am

HOWL

Werewolf Therapeutics announced initial results from its Phase 1 trial of WTX-330 as a monotherapy for immunotherapy-insensitive or resistant locally advanced or metastatic solid tumors or non-Hodgkin lymphoma. Additional results are expected in Q4 of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:12 am

QNCX

Quince Therapeutics has dosed the first patient in its Phase 3 clinical trial of EryDex for the treatment of Ataxia-Telangiectasia. This pivotal study is being conducted under a Special Protocol Assessment agreement with the U.S. FDA.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:09 am

QNCX

Quince Therapeutics has initiated the Phase 3 NEAT trial to evaluate the neurological effects of EryDex in patients with Ataxia-telangiectasia. The first patient has been dosed, and topline results are expected in the second half of 2025, with a potential New Drug Application submission in 2026.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:09 am